Illumina, Inc. (NASDAQ:ILMN – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Wednesday after Morgan Stanley lowered their price target on the stock from $150.00 to ...

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...

What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 7.5% in the morning session after Barclays downgraded ...

Illumina (NASDAQ:ILMN – Free Report) had its price objective cut by Canaccord Genuity Group from $145.00 to $135.00 in a report published on Friday,Benzinga reports. They currently have a hold rating ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Morgan Stanley analyst Tejas Savant maintained a Hold rating on Illumina (ILMN – Research Report) today and set a price target of $136.00. The ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Illumina (ILMN) to $190 from $185 following quarterly results. The ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...